By Flemming Emil Hansen
COPENHAGEN--Novo Nordisk A/S (NOVO-B.KO), the world's largest producer of insulin, said Friday that the latest trial has shown that its insulin product degludec is significantly more efficient as night-time diabetes treatment than a competitor's comparative product.
According to the Phase III trial, degludec significantly reduced the rate of hypoglycemia at night in adults with type 2 diabetes versus insulin glargine, a similar product marketed by Sanofi SA (SNY) under the name Lantus.
Degludec is an ultra-long-acting basal insulin analogue, which has a distinct slow absorption that provides a flat and stable action profile.
Novo Nordisk has filed for marketing approval of degludec with both the European the U.S. health authorities. In addition, it has been submitted for regulatory approval in Japan, Canada, Switzerland and a range of other countries.
Write to Flemming Emil Hansen at firstname.lastname@example.org
(END) Dow Jones Newswires
June 08, 2012 11:01 ET (15:01 GMT)
Copyright (c) 2012 Dow Jones & Company, Inc.